119 related articles for article (PubMed ID: 21683128)
1. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate.
Shariare MH; de Matas M; York P
Int J Pharm; 2011 Aug; 415(1-2):62-72. PubMed ID: 21683128
[TBL] [Abstract][Full Text] [Related]
2. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
4. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
[TBL] [Abstract][Full Text] [Related]
5. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.
Chiou H; Li L; Hu T; Chan HK; Chen JF; Yun J
Int J Pharm; 2007 Feb; 331(1):93-8. PubMed ID: 17052870
[TBL] [Abstract][Full Text] [Related]
6. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
7. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
8. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery.
Dhumal RS; Biradar SV; Paradkar AR; York P
Int J Pharm; 2009 Feb; 368(1-2):129-37. PubMed ID: 18996462
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
[TBL] [Abstract][Full Text] [Related]
10. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
[TBL] [Abstract][Full Text] [Related]
11. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
[TBL] [Abstract][Full Text] [Related]
12. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
13. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry.
Gaisford S; Dennison M; Tawfik M; Jones MD
Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222
[TBL] [Abstract][Full Text] [Related]
14. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers.
Jetmalani K; Young PM; Smith T; Stewart P; Traini D
Drug Dev Ind Pharm; 2012 Dec; 38(12):1504-11. PubMed ID: 22335558
[TBL] [Abstract][Full Text] [Related]
15. A novel method for the production of crystalline micronised particles.
Muhammad SA; Langrish T; Tang P; Adi H; Chan HK; Kazarian SG; Dehghani F
Int J Pharm; 2010 Mar; 388(1-2):114-22. PubMed ID: 20043982
[TBL] [Abstract][Full Text] [Related]
16. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
[TBL] [Abstract][Full Text] [Related]
17. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders.
Raula J; Thielmann F; Naderi M; Lehto VP; Kauppinen EI
Int J Pharm; 2010 Jan; 385(1-2):79-85. PubMed ID: 19879344
[TBL] [Abstract][Full Text] [Related]
18. Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree.
Kaialy W; Nokhodchi A
Int J Pharm; 2012 Nov; 437(1-2):57-69. PubMed ID: 22884837
[TBL] [Abstract][Full Text] [Related]
19. The influence of carrier morphology on drug delivery by dry powder inhalers.
Zeng XM; Martin GP; Marriott C; Pritchard J
Int J Pharm; 2000 Apr; 200(1):93-106. PubMed ID: 10845690
[TBL] [Abstract][Full Text] [Related]
20. Comparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles.
Scalia S; Traini D; Young PM; Di Sabatino M; Passerini N; Albertini B
Pharm Dev Technol; 2013 Feb; 18(1):266-73. PubMed ID: 22998063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
